Burshtein Gregory 4

What Happened Gregory Burshtein, Entera Bio Ltd.'s Chief of R&D, received a grant of 87,591 restricted stock units (RSUs) reported as an acquisition on May 7, 2026. The Form 4 lists the acquisition price as $0.00 (typical for RSU grants); the filing shows the award was approved by the company’s Board and was issued in lieu of a cash bonus.

Key Details

• Transaction type/code: Award/Grant (A) — 87,591 stock-settled restricted stock units.
• Transaction date: May 7, 2026; Form 4 filed May 8, 2026 (appears timely — Form 4 is generally due within 2 business days).
• Price/consideration: $0.00 listed (RSUs are granted, not purchased; economic value equals the company stock price at vesting).
• Vesting: RSUs vest ratably on a quarterly basis over a one-year period beginning May 1, 2026 (four quarterly vesting events).
• Footnote: Grant approved by Entera Bio’s Board and awarded in lieu of a cash bonus.
• Shares owned after transaction: Not specified in the information provided in this summary.

Context This is a compensation grant (stock-settled RSUs), not an open-market purchase or sale. RSUs convert to ordinary shares only as they vest, so receipt of RSUs is standard executive compensation and does not by itself indicate a buy/sell decision. No late filing was indicated in the available records.